Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis (Myfortic)
Recruitment status was Active, not recruiting
This is an randomized, double-blind, double-dummy trial, and the objective is to compare the efficacy and safety of Mycophenolic acid (MA) and Azathioprine (AZA), immunosuppressive drugs, in myasthenia gravis patients. This prospective study will enroll 40 myasthenia gravis (MG) patients who are poor controlled under prior steroid therapy. All subjects should be randomly assigned to MA group and AZA group that will receive routine pyridostigmine and prednisolone in combination with MA or AZA.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||Randomized, Double-blind, Double-dummy Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis|
- The ratio of two arms patients achieve minimal manifestation (MM, i.e. complete remission) [ Time Frame: One year after treatment ] [ Designated as safety issue: Yes ]
- Osserman clinical classification [ Time Frame: One year after treatment ] [ Designated as safety issue: Yes ]
- Myasthenia gravis (MG) score [ Time Frame: One year after treatment ] [ Designated as safety issue: Yes ]
|Study Start Date:||May 2009|
|Estimated Study Completion Date:||May 2011|
|Estimated Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
MA group: 1 tablet AZA placebo and 4 tablets MA (180mg/tab,720 mg/day) twice daily
Drug: Mycophenolic acid
180 mg/tablet, 4 tablets twice daily
Active Comparator: AZA
AZA group: 1 tablet AZA (50mg/tab) and 4 tablets MA placebo twice daily
1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily
This will be a double-dummy study to keep the blinded quality.
- MA group: 1 tablet AZA placebo and 4 tables MA (180 mg/tab,720 mg/day) twice daily.
AZA group: 1 tablet AZA (50mg/tab) and 4 tables MA placebo twice daily.
- When patients achieve minimal manifestation (MM, i.e. complete remission), which lead to normal daily routine, the dose of pyridostigmine should reduce to 240 mg/day (4 tablets) or less. The dose of steroid should be stepped down by 10 mg qod (every other day) for every 2 weeks until the dose achieves 40 mg qod. After that, the dose should be stepped down by 5 mg qod for every month.
- When disease progresses and is no longer maintaining minimal manifestation, the dose of steroid will be stepped up by 10 mg qod for every 2 weeks until achieve clinical stable remission. The taper rule of steroid could start again 1 month after stabilization.
- Every patient will be treated for 1 year. If the patient could not achieve MM within 1 year, the blind of individual patient will be opened and the patients will be crossed over to another medical treatment. The efficacy and safety of second medication will be observed openly until the end of study.
- When the muscle weakness worsens under established study schedule, plasmapheresis could be conducted to improve the condition rapidly.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00997412
|Principal Investigator:||Jiann-Horng Yeh, M.D.||Shin Kong Wu Ho-Su Memorial Hospital|